Fig. 5: The combination of CD73 blockade and RT remodels the TME which relies on the STING pathway.
From: Blockade of CD73 potentiates radiotherapy antitumor immunity and abscopal effects via STING pathway
A The top 20 GO BP enrichment pathways in the αCD73 + RT group (αCD73 + RT group vs control group), (B) and in the αCD73 + RT group (αCD73 + RT group vs αCD73 group). C GSVA analyses of T cell activation–associated pathways of four different groups. D DEG analyses in genes associated with CD8 function and the I-IFN pathway in TILs across different treatment groups. E Western blot analysis of the expression of cGAS, STING, pSTING, IRF3, pIRF3, and GAPDH on MC38 cells treated ± 8 Gy RT, ± CD73i, (F) and on MC38 cells extracted from both sides of mice treated ± 8 Gy RT, ±CD73i. G, H In STING inhibition experiment, H151 was administered three days prior to RT, with subsequent applications twice weekly throughout the course of treatment. Tumor growth curves of each treatment group in primary sites and abscopal sites (H), with corresponding survival data (G) are shown. Statistical variations were analyzed utilizing the One-way ANOVA (H) or Kaplan–Meier method with the log-rank test (G). Data are expressed as mean ± SEM (n = 10 per group).*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
